SYS6005

SYS6005 is a next-generation antibody-drug conjugate (ADC) targeting the receptor tyrosine kinase-like orphan receptor 1 (ROR1), which is overexpressed in various hematologic malignancies and solid tumors. The drug employs an Fc-silenced monoclonal antibody with site-specific glutamine side chain-based conjugation to minimize payload loss and deliver a homogeneous drug-to-antibody ratio. The cytotoxic payload is monomethyl auristatin E (MMAE), a microtubule inhibitor. This design aims to improve pharmacokinetics and reduce off-target toxicity compared to earlier ADCs. Developed by CSPC Megalith Biopharmaceutical (a subsidiary of CSPC Pharmaceutical Group) and licensed to Radiance Biopharma for further development outside China, SYS6005 has entered Phase 1 clinical trials for ROR1-positive hematologic cancers such as diffuse large B-cell lymphoma, mantle cell lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, as well as advanced solid tumors[2][4][6][9].

Brand names

RB-164RB164RB 164

Other names

SYS6005SYS-6005SYS 6005RB-164RB164RB 164